Last reviewed 2026-04-22 · How we verify

SB5

SB5 is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.

SB5 is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriasis, Psoriatic arthritis.

At a glance

Mechanism of action

SB5 is a biosimilar of adalimumab, a TNF-α inhibitor used to treat inflammatory and autoimmune diseases. By neutralizing TNF-α, a key pro-inflammatory cytokine, SB5 suppresses the immune response and reduces inflammation in conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

Approved indications

• Rheumatoid arthritis
• Psoriasis
• Psoriatic arthritis
• Ankylosing spondylitis
• Crohn's disease
• Ulcerative colitis

Common side effects

• Injection site reactions
• Upper respiratory tract infections
• Headache
• Serious infections
• Tuberculosis reactivation

Key clinical trials

• Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World (PHASE3)
• Early, Objective Detection of Autism. (NA)
• Treatment of Mucosal Bolivian Leishmaniasis (PHASE3)
• Congenital Heart Disease: Impact on Learning and Development in Down Syndrome (CHILD-DS)
• Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. (PHASE1, PHASE2)
• Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis (PHASE4)
• Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects (PHASE1)
• Intralesional Antimony for Bolivian Cutaneous Leishmaniasis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.